Replies to post #107072 on Biotech Values

[biomaven0]

>>Lorcaserin

With good efficacy, the FDA might be willing to relax on the target population.

I could see an awful lot of off-label prescribing even if it came to market with a limited label. Sure they would have to be very careful about marketing, but drugs for obesity hardly need a hard-sell - just look at the sales for fen/phen, all achieved with no sales or marketing (by the drug companies at least) at all.

Peter

[oldberkeley]

Re Arna: No position, ever, just got interested in it as an example of investor psychology.

When the advisory panel said no, I assumed most holders would move on, but the blind furor and desperate hope has been amazing. Now that the CRL is out, one might think that supporters would call it a day. Surprise! An astounding amount of posters on various boards are viewing this as a tremendous victory portending a stupendous share price increase in weeks to come.

It's true, we see what we want to see.